Tango Therapeutics (NASDAQ: TNGX) experienced a significant surge in its stock price during premarket trading on Monday, June 8, 2026, following the release of highly promising early-stage clinical trial results for its experimental pancreatic cancer treatment. The company's shares jumped as much as 48% to $30, according to data from Benzinga, while Reuters reported a 45% increase.
The positive momentum was driven by Tango's announcement that its combination therapy of vopimetostat and daraxonrasib achieved a 92% objective response rate (ORR) in a small but encouraging Phase 1/2 study involving 12 evaluable patients with pancreatic ductal adenocarcinoma. ORR measures the proportion of patients whose tumors shrink by a predefined amount, and in this trial, 11 out of 12 patients met that threshold.
Additionally, the company reported a six-month progression-free survival (PFS) rate of 90%, meaning that 90% of patients were alive without their disease worsening at the six-month mark. These results have prompted Tango to expedite its plans, with the company now aiming to advance the vopimetostat-daraxonrasib combo into a Phase 3 trial for first-line treatment of MTAP-deleted pancreatic cancer.
MTAP deletion is a genetic alteration found in approximately 10% to 15% of all human cancers, with particularly high prevalence in pancreatic cancer (about 40%) and lung cancer (about 15%). Vopimetostat, Tango's oral PRMT5 inhibitor, targets an enzyme that is essential for the survival of cancer cells harboring this deletion. The drug is being studied in combination with daraxonrasib, a RAS(ON) inhibitor developed by Revolution Medicines (NASDAQ: RVMD), which targets active RAS proteins—a common driver of cancer growth.
Malte Peters, CEO of Tango Therapeutics, described the trial results as offering “encouraging signals of durability” and suggested they could pave the way for a “chemotherapy-free option” for patients with MTAP-deleted pancreatic cancer. Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, noted that pancreatic cancer remains a “largely intractable disease,” underscoring the significance of these findings.
The positive data comes just a week after Revolution Medicines reported that daraxonrasib doubled survival and improved quality of life in pancreatic cancer patients, further highlighting the potential of this drug class. Tango is also exploring other combinations, including a Phase 1/2 study pairing vopimetostat with Erasca’s ERAS-0015, targeting another RAS pathway, expected to begin in the second half of 2026.
Despite the excitement, the data set is early and based on a small patient cohort, and larger trials may not replicate these results. Tango’s SEC filing noted risks such as regulatory feedback, trial timing, side effects, and funding. The company reported several Grade 3 adverse events, including rash, stomatitis, and fatigue, but no Grade 4 or 5 events were observed, and no patients discontinued treatment due to side effects.
Tango plans to finalize the Phase 3 trial design in the second half of 2026. Additionally, the company will release monotherapy data for vopimetostat in lung cancer, report initial results for TNG456 in glioblastoma, and present the pancreatic cancer combination data at an upcoming scientific conference. As of March 31, 2026, Tango reported $379.8 million in cash, cash equivalents, and marketable securities, sufficient to fund operations into 2028. The company posted a net loss of $45.5 million, or $0.32 per share, for the first quarter.
